A SNAP-SHOT OF FIRST-LINE ART TREATMENT FAILURE CASES FROM MPUMALANGA PROVINCE ON THE DECENTRALISED PHARMACOVIGILANCE PROGRAMME DATABASE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2014, Vol 2, Issue 3
Abstract
The increase in ART use comes with the inevitable increase in cases of ART treatment failure, especially that patients are living longer on ART. The main objective of this short study was to conduct an interim review of the Pharmacovigilance database at the National Pharmacovigilance Centre of South Africa in order to profile cases of treatment failure with first-line antiretroviral therapy among HIV-infected patients in Mpumalanga Province. From 2851 ADR reports, 853 were reported for male patients, 1699 females and 299 had no gender reported. A total of 271 patients were diagnosed with treatment failure. 170 of these were female, 78 male and for 23 of the reports, gender was unreported. The mean age of the patients who were reported to have treatment failure was 36 years. The highest number of treatment failure was reported from the age group 31 - 40 years with the majority being females. A strong correlation was observed between female sex and treatment failure. The South African National Pharmacovigilance Centre decentralized Pharmacovigilance database is a useful tool that can be used to consistently monitor and document ART treatment failures.
Authors and Affiliations
Dheda Mukesh, Futshane B, Kambafwile H, Fomundam H
Keywords
Related Articles
- EP ID EP349821
- DOI 10.22270/ijdra.v2i3.136
- Views 113
- Downloads 0
Regulatory requirements for Drug master file in context to Canada and Australia
Drug Master Files are required in most countries as supporting documents for the registration of drug products. DMFs generally contain information pertaining to the chemistry, manufacturing and controls (CMC) sections of...
CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES
A 505(b) (2) application is a new drug application (NDA) delineated in section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.505(b)(2) application is one that one or a lot of the investigations relied upon by the...
Regulation of Blood and Blood products in India, USA and EU
Blood and blood products are precious commodity which gives life to another person. Though we have immense discoveries and invention in science and technology, yet we cannot make blood hence, human blood has no substitut...
EXCLUSIVITY STRATEGIES OF INNOVATOR DRUG DEVELOPERS
Pharmaceutical drug development had become very costly and time consuming. There is an estimate that a drug from molecular development to marketing approvals cost $800 Millions. Drug approval process is time consuming pr...
REGULATORY REQUIREMENTS FOR DRUG PRODUCTS REGISTRATION IN SOUTH AFRICA
The South African Pharmaceutical market is one of the emerging markets in the world and it is important to study on how to register a drug in the promising pharmaceutical market in Africa. The MCC is the regulatory body...